Xeris Biopharma XERS Stock
Xeris Biopharma Price Chart
Xeris Biopharma XERS Financial and Trading Overview
| Xeris Biopharma stock price | 1.91 USD |
| Previous Close | 2.72 USD |
| Open | 2.72 USD |
| Bid | 0 USD x 3200 |
| Ask | 0 USD x 2900 |
| Day's Range | 2.66 - 2.75 USD |
| 52 Week Range | 0.97 - 3.03 USD |
| Volume | 782.97K USD |
| Avg. Volume | 1.24M USD |
| Market Cap | 372.11M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.45 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5 USD |
XERS Valuation Measures
| Enterprise Value | 475.43M USD |
| Trailing P/E | N/A |
| Forward P/E | -9.678572 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.0659122 |
| Price/Book (mrq) | 12.37443 |
| Enterprise Value/Revenue | 3.917 |
| Enterprise Value/EBITDA | -10.505 |
Trading Information
Xeris Biopharma Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 48.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.03 USD |
| 52 Week Low | 0.97 USD |
| 50-Day Moving Average | 2.53 USD |
| 200-Day Moving Average | 1.68 USD |
XERS Share Statistics
| Avg. Volume (3 month) | 1.24M USD |
| Avg. Daily Volume (10-Days) | 868.61K USD |
| Shares Outstanding | 137.31M |
| Float | 124.86M |
| Short Ratio | 5.76 |
| % Held by Insiders | 2.71% |
| % Held by Institutions | 42.71% |
| Shares Short | 7.87M |
| Short % of Float | 5.86% |
| Short % of Shares Outstanding | 5.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -64.085% |
| Operating Margin (ttm) | -47.41% |
| Gross Margin | 82.13% |
| EBITDA Margin | -37.28% |
Management Effectiveness
| Return on Assets (ttm) | -10.91% |
| Return on Equity (ttm) | -122.96% |
Income Statement
| Revenue (ttm) | 121.37M USD |
| Revenue Per Share (ttm) | 0.89 USD |
| Quarterly Revenue Growth (yoy) | 50.39% |
| Gross Profit (ttm) | 87.61M USD |
| EBITDA | -45258000 USD |
| Net Income Avi to Common (ttm) | -77780000 USD |
| Diluted EPS (ttm) | -0.55 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 95.1M USD |
| Total Cash Per Share (mrq) | 0.69 USD |
| Total Debt (mrq) | 198.42M USD |
| Total Debt/Equity (mrq) | 660.33 USD |
| Current Ratio (mrq) | 2.033 |
| Book Value Per Share (mrq) | 0.219 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -80622000 USD |
| Levered Free Cash Flow (ttm) | -33045876 USD |
Profile of Xeris Biopharma
| Country | United States |
| State | IL |
| City | Chicago |
| Address | 180 North LaSalle Street |
| ZIP | 60601 |
| Phone | 844 445 5704 |
| Website | https://www.xerispharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 355 |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Q&A For Xeris Biopharma Stock
What is a current XERS stock price?
Xeris Biopharma XERS stock price today per share is 1.91 USD.
How to purchase Xeris Biopharma stock?
You can buy XERS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xeris Biopharma?
The stock symbol or ticker of Xeris Biopharma is XERS.
Which industry does the Xeris Biopharma company belong to?
The Xeris Biopharma industry is Biotechnology.
How many shares does Xeris Biopharma have in circulation?
The max supply of Xeris Biopharma shares is 140.45M.
What is Xeris Biopharma Price to Earnings Ratio (PE Ratio)?
Xeris Biopharma PE Ratio is now.
What was Xeris Biopharma earnings per share over the trailing 12 months (TTM)?
Xeris Biopharma EPS is -0.45 USD over the trailing 12 months.
Which sector does the Xeris Biopharma company belong to?
The Xeris Biopharma sector is Healthcare.
Xeris Biopharma XERS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}